Switching tumour necrosis factor antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period
- 1 October 2007
- journal article
- other
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 66 (10), 1393-1397
- https://doi.org/10.1136/ard.2007.073569
Abstract
Objective: To evaluate the clinical response after switching from one tumour necrosis factor (TNF)α antagonist to another in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods: In this ongoing, longitudinal, observational study, data were prospectively collected on efficacy and safety since 2000 for patients starting biological treatments. The present analysis was restricted to patients with a diagnosis of spondyloarthropathy (SpA) who switched from one TNFα antagonist to another because of inadequate efficacy or adverse events. Results: In total, 589 anti-TNFα-naive patients were registered, of whom 165 had a diagnosis of SpA; 7 patients with AS and 15 with PsA received >1 TNFα antagonist. Two patients with PsA were treated with all the drugs. In all, 16 subjects switched from infliximab to etanercept, 7 from etanercept to adalimumab and 1 from etanercept to infliximab. Overall, a clinical response was seen in 75% of patients who changed from infliximab to etanercept, and in 57.1% who switched from etanercept to adalimumab. Conclusions: The findings of this study on a selected population of patients with SpA indicate that the failure of an initial TNFα antagonist does not preclude the response to another one. Further trials are needed to confirm this preliminary observation.This publication has 14 references indexed in Scilit:
- Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort studyArthritis & Rheumatism, 2007
- Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritisCurrent Opinion in Rheumatology, 2006
- First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2006
- Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University HospitalScandinavian Journal of Rheumatology, 2005
- Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.2005
- Switching between biological agents.2004
- Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative studyArthritis & Rheumatism, 1996
- A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.1994
- A RE-EVALUATION OF THE OSTEOARTICULAR MANIFESTATIONS OF PSORIASISRheumatology, 1991
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980